NOXXON's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2012

Berlin, (PresseBox) - NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, today announced that a preclinical study of the SDF-1 inhibiting Spiegelmer NOX-A12 significantly delayed post-irradiation glioblastoma recurrence. The data from this study was presented today at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, in a poster entitled Inhibition of SDF-1 (CXCL12) using the Spiegelmer NOX-A12 markedly delays the recurrence of ENU-induced rat brain tumors following irradiation.

The study, conducted in collaboration with the Stanford University School of Medicine, investigated the efficacy of NOX-A12 on brain tumor recurrences following irradiation in an animal model. In this model rats begin to die of brain tumors from approximately 120 days of age. These rats were treated with a single dose of whole brain irradiation (20 Gy) which was immediately followed by two different doses of NOX-A12 injected subcutaneously for either 4 or 8 weeks. Neither radiation nor NOX-A12 alone significantly affected the lifespan of the tumor-bearing rats; however the combination of the NOX-A12 (high or low dose) for 8 weeks and irradiation resulted in a significantly prolonged lifespan with the higher dose increasing median lifespan from 189 days for controls to 349 days (P value <0.0001)

NOX-A12 doses and treatment times in this preclinical study were chosen based on equivalents found to be safe and well tolerated in humans. Based on the results obtained from this study, the researchers believe that a clinical trial of NOX-A12 in combination with standard therapy in first-line glioblastoma patients would be justified at this point.

The abstract of this poster is available at the AACR Annual Meeting 2012 website:

Noxxon Pharma AG

NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, a chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer® therapeutics:

- NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) and is currently completing a Phase Ib study in healthy subjects and diabetics as well as a renal impairment study. A Phase II study in diabetics with renal impairment is planned to begin in April 2012.

- NOX-A12 targets SDF-1 (CXCL12), a chemokine mediator of tumor invasion, metastasis and resistance to chemotherapy, has completed Phase I. Phase IIa studies in two hematological cancers, multiple myeloma and chronic lymphocytic leukemia will begin in April 2012.

- NOX-H94 targets hepcidin, the key regulator of iron metabolism and mediator of iron restriction in anemia of chronic disease, and is currently in a comprehensive single and multiple ascending dose Phase I study. An endotoxin challenge study, designed to test the ability of NOX-H94 to block hepcidin mediated hypoferremia is currently running and a Phase II of NOX-H94 in myeloma or lymphoma patients with anemia is planned to start mid-2012.

The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team.

For more information, please visit:

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.